Follow The Filings

HCA HCA Healthcare

Health Care, filed as HCA HEALTHCARE INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 7 Owners
  • #176
  • Max 3.5%
  • Master 0.30%
  • $5.1B
  • 1 add 1 exit 6 small

In 2026 Q2 Glenn Greenberg added to HCA Healthcare, while Andreas Halvorsen sold out.

Who owns this now

Largest portfolio weights among holders, up to 3.5% (Lewis Sanders, Sanders Capital). Not free-float ownership.

  1. Lewis Sanders Reduce 3.5%
  2. Lyrical Asset Management Reduce 3.2%
  3. First Eagle Investment Manage... Add 2.1%
  4. Thomas Gayner Add 0.25%
  5. Richard Pzena Add 0.11%
  6. Bill Nygren / Oakmark Reduce 0.08%

Who owns HCA

Sorted by value, long equity only, as of 2026 Q2.

History
Lewis Sanders, Sanders Capital 3.5%, was 5.1% Small trim −1.4% 8,828,287 $3.4B History
First Eagle Investment Management 2.1% Small add +1.3% 3,295,565 $1.3B History
Lyrical Asset Management 3.2%, was 4.8% Small trim −2.2% 654,071 $255M History
Bill Nygren / Oakmark, Harris Associates L P 0.08%, was 0.10% Small trim −2.6% 154,097 $60M History
Richard Pzena, Pzena Investment Management 0.11% Small add +2.5% 96,598 $38M History
Thomas Gayner, Markel Group 0.25% Small add +2.3% 84,366 $33M History
Glenn Greenberg, Brave Warrior Advisors 0.04%, was 0.01% Add +262.6% 4,833 $1.9M History
Andreas Halvorsen, Viking Global Investors exited 2026 Q2 Last 2026 Q1 1.4% Exit −1.42% 1,075,133 $509M History

7 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by HCA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All HCA insider trades
  • None no insider bought on the open market
  • $31.1M sold by 5 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Michael R McAlevey EVP & Chief Legal & Admin Off.
    Sale
    $904K 1,694 shares at $533.37 16% of stake
    Traded Feb 18 Filed Feb 18
    ↗
  2. Christopher F. Wyatt SVP & Controller
    Sale
    $2M 4,000 shares at $505.00 8.3% of stake
    Traded Feb 11 Filed Feb 12
    ↗
  3. Jennifer Berres SVP & Chief Human Res. Officer
    Sale
    $4.1M 8,020 shares at $514.58 40% of stake
    Traded Feb 11 Filed Feb 12
    ↗
  4. Samuel N Hazen CEO
    Sale
    $21.5M 42,877 shares at $501.04 57% of stake
    Traded Feb 3 Filed Feb 5
    ↗
  5. Michael S. Cuffe EVP and Chief Clinical Officer
    Sale
    $747K 1,500 shares at $498.09 4.8% of stake
    Traded Feb 3 Filed Feb 5
    ↗
  6. Michael R McAlevey EVP & Chief Legal & Admin Off.
    Sale
    $1.8M 3,892 shares at $473.79 53% of stake
    Traded Nov 5, 2025 Filed Nov 5, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 16 stock grants, 14 share withholdings for taxes, 14 other transactions, 7 gifts, and 6 option exercises.

Congress

7 members of Congress traded HCA in the last three years: 7 buys and 7 sales. 7 members listed it in 2025 annual reports.

All Congress trades
  1. Jared Moskowitz D-FL-23 Buy $1K–$15K Jun 17 filed Jul 26
  2. Jared Moskowitz D-FL-23Child Buy $1K–$15K Jun 17 filed Jul 26
  3. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  4. Lisa C. McClain R-MI-9Spouse Sell $1K–$15K Sep 11, 2025 filed Oct 22, 2025
  5. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Aug 19, 2025 filed Sep 12, 2025
  6. Val T. Hoyle D-OR-4Spouse Sell $1K–$15K Dec 27, 2024 filed Sep 12, 2025

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
8-K 2.03,8.01 Filing Doc
10-Q Filing Doc
8-K 2.02,7.01,8.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,2.03,8.01,9.01 Filing Doc
10-Q Filing Doc
424B5 Filing Doc
8-K 5.07 Filing Doc
424B3 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income $5.24B $5.76B $6.78B

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $14.93B $16.41B $15.78B
Total non-current assets * $41.28B $43.1B $44.94B
Total assets $56.21B $59.51B $60.72B
Total current liabilities $12.66B $15.18B $16.35B
Total equity -$1.77B -$2.5B -$6.03B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $9.43B $10.51B $12.64B
Cash from investing -$5.32B -$4.93B -$4.99B
Cash from financing -$4.09B -$4.58B -$8.55B
Net change in cash $27M $998M -$893M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.